IMS Health to Announce Second-Quarter 2014 Results On July 24, 2014
DANBURY, Conn.--(BUSINESS WIRE)--IMS Health Holdings, Inc. (“IMS Health”) (NYSE:IMS) will issue its financial results for second-quarter 2014 on Thursday, July 24, 2014, before the market opens. The press release and accompanying financial information will be posted on the IMS Health Investor Relations website at http://ir.imshealth.com.
IMS Health’s management team will host a conference call and webcast to discuss the company’s results at 9:00 a.m. Eastern Time on July 24. Interested parties are invited to listen to the live event and view the presentation slides via webcast on IMS Health’s Investor Relations website at http://ir.imshealth.com. The discussion also will be available by dialing +1-800-920-6941 in the U.S. and Canada, or +1-212-231-2915 for international callers.
A replay of the webcast will be available approximately two hours after the conclusion of the live event on July 24. To access the webcast recording, visit http://ir.imshealth.com.
About IMS Health
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. By applying sophisticated analytics and proprietary application suites hosted on the IMS One intelligent cloud, the company connects more than 10 petabytes of complex healthcare data on diseases, treatments, costs and outcomes to help its clients run their operations more efficiently. Drawing on information from 100,000 suppliers, and on insights from more than 45 billion healthcare transactions processed annually, IMS Health’s approximately 10,000 employees drive results for healthcare clients globally. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes.